Status:
COMPLETED
Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database
Lead Sponsor:
University Hospital, Caen
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
In prostate cancer, whether advanced or localized, hormone therapy is a key treatment. These therapies work by lowering male hormone levels to slow the growth of cancer. More recently, a new group of...
Detailed Description
In prostate cancer, both in metastatic settings and in many localized cases, androgen suppression via Gonadotropin-Releasing Hormone (GnRH) agonists or antagonists remains the cornerstone of treatment...
Eligibility Criteria
Inclusion
- Patients had to begin a treatment with Enzalutamide, Abiraterone or Apalutamide between the 01-01-2018 and the 31-12-2022
- Patients must have a unique ID in the database, to be able to link the data
Exclusion
- Previous treatment with another novel androgen receptor signaling inhibitors
- Patients were excluded if they began a chemotherapy treatment in the 6 weeks following the beginning of Androgen Receptor Signaling Inhibitors (ARSI)
Key Trial Info
Start Date :
January 7 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
52000 Patients enrolled
Trial Details
Trial ID
NCT06902441
Start Date
January 7 2025
End Date
June 30 2025
Last Update
July 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Caen
Caen, Normandy, France, 14000